AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 4 mg once daily
Number of subjects: 929
Study 15193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 8 mg once daily
Number of subjects: 929
Study 15193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 12 mg once daily
Number of subjects: 929
Study 15193678 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 1 mg/kg twice daily
Number of subjects: 929
Study 15193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily (per-protocol analysis)
Number of subjects: 929
Study 15193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 4 mg once daily (per-protocol analysis)
Number of subjects: 929
Study 15193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 8 mg once daily (per-protocol analysis)
Number of subjects: 929
Study 15193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 12 mg once daily (per-protocol analysis)
Number of subjects: 929
Study 15193678 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 1 mg/kg twice daily (per-protocol analysis)
Number of subjects: 929
Study 10411250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methyl prednisolone sodium succinate (MPSS) 1 mg/kg
Number of subjects: 20
Study 10411250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10411250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methyl prednisolone sodium succinate (MPSS)
Number of subjects: 20
Study 7550814 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent subvirion influenza virus vaccine
Number of subjects: 186
Study 7550814 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy tubes
Number of subjects: 186
Study 7550814 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 186
Study 2127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 63
Study 2127561 — intervention group
Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 63
Study 6990861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.0 g daily) for four weeks
Number of subjects: 50
Study 6990861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6990861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.0 g daily)
Number of subjects: 50
Study 30215583 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 1760
Study 30215583 — intervention group
Group type: COMPARATOR
Intervention: Control commercial vaccine
Number of subjects: 1760
Study 28929865 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 26722
Study 28929865 — intervention group
Group type: COMPARATOR
Intervention: Chest radiographs
Number of subjects: 26722
Study 27188898 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 19
Study 27188898 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 19
Study 27188898 — intervention group
Group type: COMPARATOR
Intervention: Control oil (vegetable oil)
Number of subjects: 19
Study 24515581 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education regarding family health history (FHH) collection
Number of subjects: 43
Study 22763465 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole plus placebo (A + P)
Number of subjects: 119
Study 22763465 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus risedronate (A + R)
Number of subjects: 119
Study 22763465 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (A) alone
Number of subjects: 119
Study 20712051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 400
Study 20712051 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 400
Study 17647038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling and probiotics (Lactobacillus GG and Bifidobacterium lactis Bb12; n = 10)
Number of subjects: 30
Study 17647038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling with probiotics (n = 10)
Number of subjects: 30
Study 17647038 — intervention group
Group type: COMPARATOR
Intervention: Dietary counseling with placebo (n = 12)
Number of subjects: 30
Study 17647038 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone (n = 8)
Number of subjects: 30
Study 16336882 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox Cosmetic 20 U
Number of subjects: 0
Study 16336882 — intervention group
Group type: COMPARATOR
Intervention: Dysport 50 U
Number of subjects: 0
Study 12164449 — intervention group
Group type: COMPARATOR
Intervention: Epicardial wire placed at the lateral wall of the right atrium (Group 2)
Number of subjects: 161
Study 12164449 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire placed at Bachmann's bundle (Group 3)
Number of subjects: 161
Study 12164449 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 161
Study 10583317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (LVP) administration with minimal dose of GH-RH (0.035 microg/kg BW)
Number of subjects: 20
Study 10583317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (LVP) administration with maximal dose of GH-RH (100 microg)
Number of subjects: 20
Study 10583317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (LVP) administration with arginine (30 g over 30 min)
Number of subjects: 20
Study 10583317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (LVP) administration with clonidine (150 microg)
Number of subjects: 20
Study 10583317 — intervention group
Group type: COMPARATOR
Intervention: Normal saline administration
Number of subjects: 20
Study 7589051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem LP 300 mg
Number of subjects: 2
Study 29161998 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT plus CRT (Cognitive Rehabilitation Treatment) for two months
Number of subjects: 120
Study 29161998 — intervention group
Group type: COMPARATOR
Intervention: MMT plus control intervention
Number of subjects: 120
Study 26923256 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg
Number of subjects: 197
Study 26923256 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 10 mg
Number of subjects: 197
Study 25530384 — intervention group
Group type: COMPARATOR
Intervention: 4 mg doxazosin XL
Number of subjects: 162
Study 25530384 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin XL
Number of subjects: 162
Study 25530384 — intervention group
Group type: COMPARATOR
Intervention: 4 mg doxazosin XL (group 1b)
Number of subjects: 162
Study 25530384 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin XL (group 1b)
Number of subjects: 162
Study 22790267 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time quantitative polymerase chain reaction using SYBR Green I dye for detecting ABO chimerism at nucleotide polymorphism sites 261, 467, and 803.
Number of subjects: 76
Study 22790267 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time quantitative polymerase chain reaction for detecting ABO chimerism.
Number of subjects: 76
Study 21691253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO)
Number of subjects: 154
Study 21691253 — intervention group
Group type: COMPARATOR
Intervention: Sunflower Oil (SO)
Number of subjects: 154
Study 19446151 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablet formulation of arbidol 200 mg
Number of subjects: 20
Study 19446151 — intervention group
Group type: COMPARATOR
Intervention: Branded capsule formulation of arbidol 200 mg
Number of subjects: 20
Study 17224848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation of lopinavir/ritonavir (800/200 mg or 400/100 mg)
Number of subjects: 0
Study 17224848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation of lopinavir/ritonavir
Number of subjects: 0
Study 17224848 — intervention group
Group type: COMPARATOR
Intervention: Soft-gelatin capsule (SGC) formulation of lopinavir/ritonavir
Number of subjects: 0
Study 15042010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg every 4 hours for 24 hours)
Number of subjects: 217
Study 15042010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg every 4 hours for 24 hours)
Number of subjects: 217
Study 15042010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic PGF(2alpha) (40 mg followed by oxytocin infusion)
Number of subjects: 217
Study 15042010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 217
Study 15042010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 217
Study 15042010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic PGF(2alpha)
Number of subjects: 217
Study 11722960 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone
Number of subjects: 15
Study 11722960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrophylloquinone
Number of subjects: 15
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to 54 Gy to the breast (XRT group)
Number of subjects: 381
Study 9137791 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (non XRT group)
Number of subjects: 381
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Comedo cancer
Number of subjects: 381
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobular cancers
Number of subjects: 381
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic appearance as circular/oval shaped density
Number of subjects: 381
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic appearance as a stellate lesion with microcalcifications
Number of subjects: 381
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 381
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Comedo cancers (multivariate analysis)
Number of subjects: 381
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic appearance of a stellate lesion with microcalcifications (multivariate analysis)
Number of subjects: 381
Study 9137791 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients > 60 years of age without comedo or lobular cancers
Number of subjects: 381
Study 8192104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acivicin 60 mg/m2 as a continuous intravenous infusion over 72 hours, repeated every 28 days
Number of subjects: 82
Study 8192104 — intervention group
Group type: COMPARATOR
Intervention: Etoposide 120 mg/m2 daily on days 1, 2, and 3 and cisplatin 60 mg/m2 intravenously on day 1, repeated every 28 days
Number of subjects: 82
Study 8192104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acivicin
Number of subjects: 82
Study 3300325 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 50
Study 3300325 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 50
Study 3300325 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy and No therapy
Number of subjects: 50
Study 29235967 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating working postures
Number of subjects: 45
Study 29235967 — intervention group
Group type: COMPARATOR
Intervention: Sitting posture
Number of subjects: 45
Study 27612446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis Optimal Health Program (DOHP)
Number of subjects: 96
Study 27612446 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study 23822820 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing training for pharmacists
Number of subjects: 542
Study 22020244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital cooling using a rapid infusion of up to two litres ice-cold Hartmann's solution (82 patients)
Number of subjects: 163
Study 22020244 — intervention group
Group type: COMPARATOR
Intervention: Cooling after hospital admission (81 patients)
Number of subjects: 163
Study 22020244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital cooling in patients with a cardiac cause of arrest (47 patients)
Number of subjects: 163
Study 22020244 — intervention group
Group type: COMPARATOR
Intervention: Hospital cooled patients with a cardiac cause of arrest (43 patients)
Number of subjects: 163
Study 20810095 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical shaver debridement (MSD)
Number of subjects: 60
Study 20810095 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency-based chondroplasty (RFC)
Number of subjects: 60
Study 19717804 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduate Record Exam verbal score (GRE-V)
Number of subjects: 235
Study 19717804 — intervention group
Group type: EXPERIMENTAL
Intervention: Undergraduate grade point average (UGPA)
Number of subjects: 235
Study 19717804 — intervention group
Group type: EXPERIMENTAL
Intervention: Underrepresented minority status (URMS)
Number of subjects: 235
Study 19717804 — intervention group
Group type: EXPERIMENTAL
Intervention: GRE-V, UGPA, and prior graduate degree
Number of subjects: 235
Study 19717804 — intervention group
Group type: EXPERIMENTAL
Intervention: GRE-V
Number of subjects: 235
Study 19717804 — intervention group
Group type: EXPERIMENTAL
Intervention: Course Mastery
Number of subjects: 235
Study 15681958 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Caine Patch
Number of subjects: 64
Study 15681958 — intervention group
Group type: COMPARATOR
Intervention: Placebo Patch
Number of subjects: 64
Study 12958723 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation group (Group A) - Heparin intravenously with target aPTT 50-70 seconds
Number of subjects: 153
Study 12958723 — intervention group
Group type: COMPARATOR
Intervention: Non-anticoagulation group (Group B) - No intravenous heparin
Number of subjects: 153
Study 12958723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study 12958723 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation group (Group A)
Number of subjects: 153
Study 12958723 — intervention group
Group type: COMPARATOR
Intervention: Non-anticoagulation group (Group B)
Number of subjects: 153
Study 10543590 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic suture repair
Number of subjects: 56
Study 10543590 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair with absorbable polyglyconate tack
Number of subjects: 56
Study 10543590 — intervention group
Group type: EXPERIMENTAL
Intervention: Open capsular shift with repair of the Bankart lesion
Number of subjects: 56
Study 8762769 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic spectacle frames (7 frames)
Number of subjects: 2
Study 8762769 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal spectacle frames (3 frames)
Number of subjects: 2
Study 8762769 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical visual field defects calculation
Number of subjects: 2
Study 8762769 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings regarding spectacle frames
Number of subjects: 2
Study 8762769 — intervention group
Group type: EXPERIMENTAL
Intervention: Frames allowing adequate vision at night
Number of subjects: 2
Study 1990794 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous verapamil
Number of subjects: 8
Study 1990794 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 10% intravenous calcium chloride followed by 10 mg of intravenous verapamil
Number of subjects: 8
Study 1990794 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of 0.9% intravenous sodium chloride followed by 10 mg of intravenous verapamil
Number of subjects: 8
Study 1990794 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of 10% intravenous calcium chloride followed by 4 ml of 0.9% intravenous sodium chloride
Number of subjects: 8
Study 6848891 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy with azathioprine therapy for 1 year
Number of subjects: 35
Study 6848891 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy without azathioprine therapy for 1 year
Number of subjects: 35
Study 31267524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 42
Study 31267524 — intervention group
Group type: EXPERIMENTAL
Intervention: Random skin biopsy combined with imaging
Number of subjects: 42
Study 28850021 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ (Tocilizumab)
Number of subjects: 741
Study 26585832 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC-RIPostC
Number of subjects: 65
Study 26585832 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 24405800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (Pradaxa)
Number of subjects: 92
Study 22196293 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dexamethasone via iontophoresis
Number of subjects: 82
Study 22196293 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dexamethasone injection
Number of subjects: 82
Study 22196293 — intervention group
Group type: COMPARATOR
Intervention: 10 mg triamcinolone injection
Number of subjects: 82
Study 20303788 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil supplementation (2.1 g/day) for 90 days
Number of subjects: 40
Study 20303788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no omega-3 supplementation)
Number of subjects: 40
Study 17673448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (aspirin plus clopidogrel)
Number of subjects: 2289
Study 17673448 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2289
Study 14730323 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate balloon angioplasty (PTRA)
Number of subjects: 106
Study 14730323 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy followed by angioplasty after 3 months (Med-PTRA)
Number of subjects: 106
Study 11377642 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of antenatal care (median of 5 visits)
Number of subjects: 25526
Study 11377642 — intervention group
Group type: COMPARATOR
Intervention: Standard model of antenatal care (median of 8 visits)
Number of subjects: 25526
Study 9598265 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Macintosh blade
Number of subjects: 30
Study 7893284 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate 200 mg 3 times a day
Number of subjects: 27
Study 7893284 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 3058130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 120
Study 3058130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30777027 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous anterior QL block (CQLB)
Number of subjects: 63
Study 30777027 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 63
Study 28978520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic-use method (MUM)
Number of subjects: 29
Study 28978520 — intervention group
Group type: COMPARATOR
Intervention: Self-study method (STMM)
Number of subjects: 29
Study 25738345 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap with connective tissue graft (CAF + CTG)
Number of subjects: 25
Study 25738345 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap alone (CAF)
Number of subjects: 25
Study 25738345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (CAF + CTG and CAF)
Number of subjects: 25
Study 24209458 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Group (ESG) exercise program for 1 h, three days/week, for 48 weeks.
Number of subjects: 31
Study 24209458 — intervention group
Group type: COMPARATOR
Intervention: Delayed Start Group (DSG) exercise program for 1 h, three days/week, from weeks 24-48.
Number of subjects: 31
Study 24209458 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Group (ESG) exercise program.
Number of subjects: 31
Study 24209458 — intervention group
Group type: COMPARATOR
Intervention: Delayed Start Group (DSG) exercise program.
Number of subjects: 31
Study 22571552 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 30
Study 22571552 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 30
Study 19116603 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM(+) (with adjuvant)
Number of subjects: 524
Study 19116603 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM(‐) (without adjuvant)
Number of subjects: 524
Study 19116603 — intervention group
Group type: COMPARATOR
Intervention: MPSV4 (licensed unconjugated quadrivalent polysaccharide vaccine)
Number of subjects: 524
Study 18175550 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 54
Study 18175550 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 54
Study 18175550 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 54
Study 15022127 — intervention group
Group type: EXPERIMENTAL
Intervention: HaloLite Paediatric Nebulizer (HPN)
Number of subjects: 14
Study 15022127 — intervention group
Group type: COMPARATOR
Intervention: pressurized metered dose inhaler and valved holding chamber (pMDI VHC)
Number of subjects: 14
Study 11533570 — intervention group
Group type: COMPARATOR
Intervention: Step aerobics
Number of subjects: 45
Study 11533570 — intervention group
Group type: COMPARATOR
Intervention: Aerobic dancing
Number of subjects: 45
Study 9661564 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 120
Study 9661564 — intervention group
Group type: COMPARATOR
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 120
Study 7633110 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-triggered turbo spin-echo (TSE)
Number of subjects: 22
Study 7633110 — intervention group
Group type: COMPARATOR
Intervention: ECG-triggered conventional spin-echo (CSE)
Number of subjects: 22
Study 7633110 — intervention group
Group type: COMPARATOR
Intervention: nontriggered turbo spin-echo (TSE)
Number of subjects: 22